Electrocardiographic changes in spontaneous pneumothorax.

not just a surrogate for serosal effusions? Int J Cardiol Feb 3 2010;146(3):473–4. [10] Turgut O, Tandogan I, Yilmaz MB, Gul I, Zorlu A. CA125 in heart failure: implications for immunoinflammatory activity. Int J Cardiol Jan 7 2011;146(1):99–100. [11] Kosar F, Aksoy Y, Ozguntekin G, Ozerol I, Varol E. Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail May 2006;8(3):270–4. [12] Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AA, Leguit P. CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol Mar 1994;47(3):263–5. [13] Zeimet AG, Marth C, Offner FA, et al. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol Sep 1996;62(3):384–9. [14] Do JY, Kim YL, Park JW, et al. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis. Perit Dial Int Jun 2008;28(Suppl 3):S101–6. [15] Pajek J, Kveder R, Bren A, et al. Short-term effects of a new bicarbonate/lactatebuffered and conventional peritoneal dialysis fluid on peritoneal and systemic inflammation in CAPD patients: a randomized controlled study. Perit Dial Int JanFeb 2008;28(1):44–52. [16] Scholler N, Urban N. CA125 in ovarian cancer. Biomark Med Dec 2007;1(4): 513–23. [17] Bast Jr RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers Oct-Dec 1998;13(4):179–87. [18] Goldman PA. CA 125: value or addiction? Cancer Jun 15 2010;116(12):2854–5. [19] Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet Oct 2 2010;376(9747):1155–63. [20] Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J Dec 2000;140(6):840–7. [21] Nunez J, Sanchis J, Bodi V, et al. Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur Heart J Jul 2010;31(14):1752–63.